June 13, 2024

Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 28, 2026

    Teva Allowed New Mifepristone Claim But Not New Defendant

    A California federal judge gave Teva permission to update its antitrust suit accusing Corcept Therapeutics of using patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment while refusing to let Teva add another specialty pharmacy as a defendant.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login